Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 1/2017

06.08.2016 | Original Article

The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma

verfasst von: Yeongjoo Lee, Ie Ryung Yoo, Sun Ha Boo, Hyoungwoo Kim, Hye Lim Park, Joo Hyun O

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).

Methods

From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.

Results

The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).

Conclusion

FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
Literatur
1.
Zurück zum Zitat Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed
2.
Zurück zum Zitat Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.CrossRefPubMed Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.CrossRefPubMed
3.
Zurück zum Zitat Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res. 2002;22:3637–41.PubMed Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res. 2002;22:3637–41.PubMed
4.
Zurück zum Zitat Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816–20.CrossRefPubMedPubMedCentral Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816–20.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–7.CrossRefPubMed Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–7.CrossRefPubMed
6.
Zurück zum Zitat Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.CrossRefPubMed Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.CrossRefPubMed
7.
Zurück zum Zitat Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.CrossRefPubMed Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.CrossRefPubMed
8.
Zurück zum Zitat Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRefPubMed Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRefPubMed
9.
Zurück zum Zitat Albazaz R, Patel CN, Chowdhury FU, Scarsbrook AF. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging. 2013;4:691–700.CrossRefPubMedPubMedCentral Albazaz R, Patel CN, Chowdhury FU, Scarsbrook AF. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging. 2013;4:691–700.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–51.CrossRefPubMed Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145–51.CrossRefPubMed
11.
Zurück zum Zitat Park SK, Kim YS, Kim SG, Jang JY, Moon JH, Lee MS, et al. Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma. Korean J Hepatol. 2010;16:325–8.CrossRefPubMedPubMedCentral Park SK, Kim YS, Kim SG, Jang JY, Moon JH, Lee MS, et al. Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma. Korean J Hepatol. 2010;16:325–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, et al. Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46:1158–63.PubMed Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, et al. Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46:1158–63.PubMed
13.
Zurück zum Zitat Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2014;2014:247693.CrossRefPubMedPubMedCentral Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2014;2014:247693.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Rad. 2016. Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Rad. 2016.
15.
Zurück zum Zitat Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155–64.CrossRefPubMed Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155–64.CrossRefPubMed
16.
Zurück zum Zitat Hepatobiliary (NCCN guideline). NCCN clinical practice guidelines in oncology, Version 2. 2015. Hepatobiliary (NCCN guideline). NCCN clinical practice guidelines in oncology, Version 2. 2015.
17.
Zurück zum Zitat Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRefPubMed Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRefPubMed
18.
Zurück zum Zitat Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012;147:1107–13.CrossRefPubMed Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012;147:1107–13.CrossRefPubMed
19.
Zurück zum Zitat Sonbare DJ. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group. Ann Surg. 2014;259:e36.CrossRefPubMed Sonbare DJ. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group. Ann Surg. 2014;259:e36.CrossRefPubMed
20.
Zurück zum Zitat de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.CrossRefPubMed de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.CrossRefPubMed
21.
Zurück zum Zitat Feydy A, Vilgrain V, Denys A, Sibert A, Belghiti J, Vullierme MP, et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol. 1999;172:73–7.CrossRefPubMed Feydy A, Vilgrain V, Denys A, Sibert A, Belghiti J, Vullierme MP, et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol. 1999;172:73–7.CrossRefPubMed
22.
Zurück zum Zitat Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029–35.CrossRefPubMed Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029–35.CrossRefPubMed
23.
Zurück zum Zitat Park TG, Yu YD, Park BJ, Cheon GJ, Oh SY, Kim DS, et al. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. Clin Nucl Med. 2014;39:1–7.CrossRefPubMed Park TG, Yu YD, Park BJ, Cheon GJ, Oh SY, Kim DS, et al. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. Clin Nucl Med. 2014;39:1–7.CrossRefPubMed
24.
Zurück zum Zitat Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467–72.CrossRefPubMed Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467–72.CrossRefPubMed
25.
Zurück zum Zitat Jo I, Won KS, Kim SH, Song B-I, Kang YN, Kim JY. Catheter Tract Implantation Metastasis Diagnosed by F-18 FDG PET/CT After Percutaneous Transhepatic Biliary Drainage for Hilar Cholangiocarcinoma. Nucl Med Mol Imaging. 2014;48:326–7.CrossRefPubMedPubMedCentral Jo I, Won KS, Kim SH, Song B-I, Kang YN, Kim JY. Catheter Tract Implantation Metastasis Diagnosed by F-18 FDG PET/CT After Percutaneous Transhepatic Biliary Drainage for Hilar Cholangiocarcinoma. Nucl Med Mol Imaging. 2014;48:326–7.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047–54.CrossRefPubMed Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047–54.CrossRefPubMed
27.
Zurück zum Zitat Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22:1277–85.CrossRefPubMed Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22:1277–85.CrossRefPubMed
28.
Zurück zum Zitat Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43–50.CrossRefPubMed Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43–50.CrossRefPubMed
29.
Zurück zum Zitat Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002;183:679–85.CrossRefPubMed Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002;183:679–85.CrossRefPubMed
30.
Zurück zum Zitat Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2009;122:2286-91. Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2009;122:2286-91.
31.
Zurück zum Zitat Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Narita M, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci. 2011;18:39–46.CrossRefPubMed Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Narita M, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci. 2011;18:39–46.CrossRefPubMed
32.
Zurück zum Zitat Cho KM, Oh DY, Kim TY, Lee KH, Han SW, Im SA, et al. Metabolic Characteristics of Advanced Biliary Tract Cancer Using F-18-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist. 2015;20:926–33.CrossRefPubMedPubMedCentral Cho KM, Oh DY, Kim TY, Lee KH, Han SW, Im SA, et al. Metabolic Characteristics of Advanced Biliary Tract Cancer Using F-18-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist. 2015;20:926–33.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Min M, Lin P, Lee MT, Shon IH, Lin M, Forstner D et al. Prognostic role of metabolic parameters of F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015; doi: 10.1007/s00259-015-3104-8. Min M, Lin P, Lee MT, Shon IH, Lin M, Forstner D et al. Prognostic role of metabolic parameters of F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015; doi: 10.​1007/​s00259-015-3104-8.
34.
Zurück zum Zitat Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, et al. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging. 2014;14:2.PubMedPubMedCentral Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, et al. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging. 2014;14:2.PubMedPubMedCentral
Metadaten
Titel
The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma
verfasst von
Yeongjoo Lee
Ie Ryung Yoo
Sun Ha Boo
Hyoungwoo Kim
Hye Lim Park
Joo Hyun O
Publikationsdatum
06.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 1/2017
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0440-y

Weitere Artikel der Ausgabe 1/2017

Nuclear Medicine and Molecular Imaging 1/2017 Zur Ausgabe